The Paoli Calmettes Institute (IPC), a private not-for-profit comprehensive cancer center in Marseille, France, has initiated a collaboration with Innate Pharma SA (Euronext Paris: FR0010331421 – IPH)...

Cash, cash equivalents and financial instruments of the Company amounted to 59.2 million euros as at March 31, 2015 Co-development and commercialization agreement with AstraZeneca including an upfront...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting (“AGM”) which took place on April 27, 2015, in Marseille, France : A number of 27,560,731 votes were...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that it has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, its global biologics...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory...

Treatment stopped in one arm of the study with remaining two arms continuing as per protocol Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on April 27, 2015, at 11:00 am in its headquarters, 117 avenue de Luminy, F-13009...

The trial rationale and protocol were presented at the “Targeted Anticancer Therapies” congress in Paris Phase I/II of IPH2201 as a single agent will begin in the next few months Innate Pharma SA (the...

€50m capital increase in June subscribed by specialized investors Cash horizon to the end of 2017 Acquisition of IPH2201, anti-NKG2A antibody, and start of Phase II clinical development Expected in...

First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...